REDDING, Calif., May 23, 2024 /PRNewswire/ -- According to a new market research report titled, 'Continuous Bioprocessing Market by Product (Filtration, Chromatography, Bioreactor, Incubator, Centrifuge, Reagents) Process (Upstream, Downstream) Application (Monoclonal Antibodies, Vaccines, Plasma Fractionation, R&D) End User—Global Forecast to 2031",  published by Meticulous Research^®, the continuous bioprocessing market is projected to reach $1.32 billion by 2031 at a CAGR of 19.6% from 2024 to 2031.

Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=5079

Continuous bioprocessing has become a major trend in biopharmaceutical manufacturing due to its agility, flexibility, efficiency, and robustness. It reduces the number of steps and holds, requires smaller facilities with limited equipment, and improves product quality, enabling real-time release. Advantages such as cost efficiency and improved product quality are expected to drive the adoption of continuous bioprocessing in the biopharmaceutical industry in the coming years. Continuous bioprocessing involves the use of filtration, chromatography, centrifugation, bioreactors, incubators/shakers, sterilizers, cell culture media, buffers, and reagents.

Bioprocessing 4.0 Generating Growth Opportunities for Market Stakeholders

Bioprocessing 4.0 is defined as an end-to-end connected bioprocess, where all equipment and systems in the process are connected digitally, forming the Industrial Internet of Things (IIoT) to run, control, and enhance the process through feedback loops and Machine Learning (ML) or Artificial Intelligence (AI).

The rapid development in emerging economies, progressing research on biologics, and the increasing penetration of biopharmaceuticals have created tremendous opportunities for biopharma manufacturers, boosting the demand for continuous bioprocessing technologies. The manufacture of biologics has grown significantly over the last five years. The industry is shifting towards Bioprocessing 4.0, a term derived from Industry 4.0, a national strategic initiative launched by the German government in 2010. The Biopharma 4.0 concept has steadily gained momentum over the past several years, generating market growth opportunities.

Bioprocessing 4.0 integrates automation technologies such as robotics, big data analytics, artificial intelligence, and machine learning, among others, to improve bioprocesses in the pharmaceutical industry. AI-driven predictive analytics and modeling help in biopharmaceutical process development, reducing costs, time, and risks associated with experiment-based approaches. Biopharmaceutical manufacturers are under constant pressure to develop biopharmaceuticals in shorter timeframes without compromising product safety and quality, driving the demand for Bioprocessing 4.0.

Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=5079 

The key players operating in the continuous bioprocessing market are 3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Eppendorf AG (Germany), Danaher Corporation (U.S.), Merck KGaA (Germany), Repligen Corporation (U.S.), Getinge AB (Sweden), Bionet (Spain), Corning Incorporated (U.S.), Fujifilm Holdings Corporation (Japan), Entegris, Inc. (U.S.), and Meissner Corporation (U.S.).

Among all the products studied in this report, the filtration systems & consumables segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is driven by the high preference for filtration methods as a separation technique in bioprocessing, technological advancements in filtration devices, and the need for high cell densities in controlling the bioburden in biopharmaceuticals. Investments by market players in advancing filtration systems also support the growth of this segment. For instance, in May 2023, 3M Company (U.S.) invested $150 million in advancing its biopharma filtration technology. The investment includes facility and equipment improvements in 3M manufacturing facilities in Europe.

Among all the process types studied in this report, in 2024, the downstream processes segment is expected to account for the larger share of the continuous bioprocessing market. The segment's large share is attributed to the high adoption of downstream processing in continuous manufacturing to check the final product quality, the increasing use of downstream bioprocessing for vaccine production and viral inactivation, and the increasing number of CMOs engaged in downstream processing. The players in this market are focused on strategic collaborations to advance downstream processes. For instance, in January 2023, Sartorius AG (Germany) collaborated with RoosterBio, Inc. (U.S.) to advance downstream purification processes in exosome manufacturing.

Have Specific Research Needs? Request a Customized Report-

https://www.meticulousresearch.com/request-customization/cp_id=5079 

Among all the applications studied in this report, in 2024, the commercial applications segment is expected to account for the larger share of the continuous bioprocessing market. Increasing investments in constructing facilities compatible with continuous bioprocessing for the commercial manufacture of biopharmaceuticals is a key factor supporting this segment's large share. The implementation of continuous bioprocessing in commercial biopharmaceutical manufacturing improves productivity and reduces manufacturing costs, reducing the prices of biopharmaceutical products, making medicines more accessible, and improving the quality of care. The shift in focus toward personalized medicines and individualized biologics also supports the adoption of continuous biomanufacturing in commercial applications.

Among all the end users studied in this report, the CDMOs & CROs segment is expected to register the highest CAGR during the forecast period. The demand for continuous bioprocessing among CDMOs & CROs is expected to increase during the forecast period, mainly due to the flexibility offered by continuous bioprocessing and rising investments and partnerships among CDMOs and CROs. Continuous manufacturing reduces the overall process duration, helping save on operational and utility costs. These benefits are expected to support the adoption of continuous bioprocessing among CDMOs & CROs, boosting the growth of this segment.

Geographically, in 2024, North America is expected to account for the largest share of the continuous bioprocessing market. North America's major market share is attributed to the high R&D expenditure, growth in the pharmaceutical industry, and increasing pharmaceutical expenditure in the region. Also, initiatives supporting the uptake of biosimilars, and the rising number of biopharmaceutical approvals are accelerating research on precision medicines. According to the U.S. FDA, in 2023, 25 biologics were approved, compared to 14 in 2022.

Browse In-depth Report Now- https://www.meticulousresearch.com/product/continuous-bioprocessing-market-5079 

Scope of the Report:

Continuous Bioprocessing Market Assessment—by Product

• Filtration Systems & Consumables
• Chromatography Systems & Consumables
• Cell Culture Media, Buffers, and Reagents
• Incubators & Shakers
• Bioreactors
• Centrifuges
• Sterilizers
• Other Instruments & Consumables

Note: Other instruments & consumables include membrane absorbers, connectors & clamps, and sampling systems.

Continuous Bioprocessing Market Assessment—by Process Type

• Upstream Processes
• Downstream Processes

Continuous Bioprocessing Market Assessment—by Application

• Commercial Applications
• Monoclonal Antibodies (mAb) Production
• Cell & Gene Therapy Production
• Vaccine Manufacturing
• Plasma Fractionation
• Recombinant Protein Production
• Research & Development (R&D) Applications

Continuous Bioprocessing Market Assessment—by End User

• Pharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organizations (CDMOs) & Contract Research Organizations (CROs)
• Academic & Research Institutes

Continuous Bioprocessing Market Assessment—by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Switzerland
  • Ireland
  • Denmark
  • Belgium
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
• Middle East & Africa

Unlock Opportunities: Buy Now- https://www.meticulousresearch.com/Checkout/13717155 

Related Reports:

Biopharmaceutical Processing Equipment and Consumables Market by Product Type (Filtration, Chromatography [Consumables, Equipment], Disposable Bioreactors, Cell Culture Media, Shakers, Services), Application (Vaccine, mAb, R&D), and End User- Forecast to 2029

Antibody Production Market by Product [Bioreactors (Single-use, Reusable), Chromatography, Filtration, Cell Lines, Media, Buffers, Resins], Antibody [Monoclonal, Polyclonal], Source [Mice, Rabbit], Process [Downstream, Upstream] – Global Forecast to 2031

Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred-tank, Wave-induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (mAb, Vaccine), Research], End User - Global Forecast to 2030

Chromatography Market by Product (Systems, Columns, Reagents, Vials, Fittings, Detectors, Pumps, Software), Technology (HPLC, LPLC, Flash Chromatography, GC, TLC), End User (Pharmaceutical, Academic, F&B, Environmental, Hospital) – Global Forecast to 2030

Cell Culture Market by Product [Consumables (Media, Reagents, Sera, Cell Lines), Equipment (Bioreactor, Centrifuge, Cell Counter)], Application (Bioproduction, Cancer Research, Stem Cell, Diagnostic), End User (Pharma, Academic) - Global Forecast to 2029

Related Blogs:

Top 10 Companies in Continuous Bioprocessing Market

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Content Source: https://www.meticulousresearch.com/pressrelease/266/continuous-bioprocessing-market-2031

Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg

View original content:https://www.prnewswire.com/news-releases/continuous-bioprocessing-market-to-be-worth-1-32-billion-by-2031---exclusive-report-by-meticulous-research-302154187.html

SOURCE Meticulous Market Research Pvt. Ltd.